REG - AstraZeneca PLC - Notice of AGM

AstraZenecaAnnouncement

07/03/2024 11:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240307:nRSG0023Ga&default-theme=true

RNS Number : 0023G  AstraZeneca PLC  07 March 2024

7 March 2024 11:00 GMT

 

Notice of Annual General Meeting

 

AstraZeneca PLC (the Company) announced today the publication of its Notice of
Annual General Meeting 2024 and Shareholders' Circular (the Notice).

 

The Company's Annual General Meeting (AGM) will be digitally-enabled and will
be held on Thursday 11 April at 14:30 (BST). Full details and joining
instructions are set out in the Notice.

 

The Notice, proxy form and 2020 Performance Share Plan have been submitted to
the National Storage Mechanism and will shortly be available for inspection at
https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism) . The Notice is also
available on the Company's website at www.astrazeneca.com/noticeofmeeting2024.

 

The Notice is being despatched to shareholders today.

 

The business to be conducted at the AGM is summarised below:

1.   To receive the Company's Accounts, the Reports of the Directors and
Auditor and the Strategic Report for the year ended 31 December 2023

2.   To confirm the 2023 interim dividends

3.   To re-appoint PricewaterhouseCoopers LLP as Auditor

4.   To authorise the Directors to agree the remuneration of the Auditor

5.   To elect or re-elect Directors

6.   To approve the annual statement of the Chair of the Remuneration
Committee and the Annual Report on Remuneration for the year ended 31 December
2023

7.   To approve the Directors' Remuneration Policy

8.   To approve amendments to the AstraZeneca Performance Share Plan 2020

9.   To authorise limited political donations

10. To authorise the Directors to allot shares

11. To authorise the Directors to disapply pre-emption rights

12. To authorise the Directors to further disapply pre-emption rights for
acquisitions and specified capital investments

13. To authorise the Company to purchase its own shares

14. To reduce the notice period for general meetings

Pursuant to Regulation 41 of the Uncertificated Securities Regulations 2001,
only holders of ordinary shares entered in the register of members of the
Company by 6.30pm (BST) on 9 April 2024 (or their duly appointed proxies), or
if this meeting is adjourned, in the register of members by 6.30pm (BST) two
days prior to any adjourned meeting, are entitled to attend or vote at the AGM
in respect of the number of ordinary shares registered in their name at that
time. Changes to the entries in the register of members after 6.30pm (BST) on
9 April 2024, or if this meeting is adjourned, in the register of members
after 6.30pm (BST) two days prior to any adjourned meeting, shall be
disregarded in determining the rights of any person to attend or vote at the
AGM. The Record Date applied to the Euroclear Sweden system to determine
entitlement to participate and vote at the AGM is close of business on 2 April
2024.

 

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries
and its innovative medicines are used by millions of patients worldwide.
Please visit astrazeneca.com (http://www.astrazeneca.com/) and follow the
Company on social media @AstraZeneca (http://www.twitter.com/AstraZeneca) .

 

Contacts

For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.

 

 

Adrian Kemp

Company Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAUPUAGWUPCGUM